113118-83-5

Basic information

• Product Name: 5-METHOXY-PYRIDINE-3-CARBALDEHYDE
• Synonyms: 3-FORMYL-5-METHOXYPYRIDINE;5-METHOXY-3-PYRIDINECARBOXALDEHYDE;5-METHOXYNICOTINALDEHYDE;5-METHOXY-PYRIDINE-3-CARBALDEHYDE;5-Methoxypyridine-3-carboxaldehyde;3-Pyridinecarboxaldehyde,5-methoxy-(9CI);3-METHOXY-5-PYRIDINECARBOXALDEHYDE;5-methoxy-3-pyridinecorbaxaldehyde
• CAS NO: 113118-83-5
• Molecular Formula: C₇H₇NO₂
• Molecular Weight: 137.14
• Product Categories: PYRIDINE;Aldehydes;Pyridines;Heterocyclic Compounds;Building Blocks;C7 and C8;Heterocyclic Building Blocks;Heterocycle-Pyridine series
• Mol File: 113118-83-5.mol
• Article Data: 15

Chemical Properties

• Melting Point: 28-32 °C
• Boiling Point: 262.132 °C at 760 mmHg
• Flash Point: 100 °C
• Appearance: /
• Density: 1.159 g/cm³
• Vapor Pressure: 0.011mmHg at 25°C
• Refractive Index: 1.551
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 2.52±0.10(Predicted)
• CAS DataBase Reference: 5-METHOXY-PYRIDINE-3-CARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHOXY-PYRIDINE-3-CARBALDEHYDE(113118-83-5)
• EPA Substance Registry System: 5-METHOXY-PYRIDINE-3-CARBALDEHYDE(113118-83-5)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-43
• Safety Statements: 36/37
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 113118-83-5(Hazardous Substances Data)

Usage

Chemical Properties

White to yellow to orange to brown solid

InChI:InChI=1/C7H7NO2/c1-10-7-2-6(5-9)3-8-4-7/h2-5H,1H3

Upstream product

• 50720-12-2 3-bromo-5-methoxypyridine 
• 68-12-2 N,N-dimethyl-formamide 
• 113118-68-6 3-Methoxy-2H-pyridine-1-carboxylic acid phenyl ester 
• 7295-76-3 3-methoxypyridine 
• 20826-01-1 Ethyl 5-methoxynicotinate 
• 625-92-3 3,5-dibromopyridine 
• 113118-74-4 5-Formyl-3-methoxy-2H-pyridine-1-carboxylic acid phenyl ester 
• 937202-11-4 (5-methoxypyridin-3-yl)methanol 

Downstream Products

• 1426389-05-0 4-(2-(4-(5-methoxypyridin-3-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile 
• 886364-74-5 1-(5-methoxypyridin-3-yl)ethanone 
• 298204-74-7 5-(methyloxy)pyridine-3-carbonitrile 
• 118420-38-5 (E)-N-[4-(4-Benzhydryl-piperazin-1-yl)-butyl]-3-(5-methoxy-pyridin-3-yl)-acrylamide 
• 118420-39-6 N-[3-(5-hydroxy-3-pyridyl)acryloyl]4-(4-diphenylmethyl-1-piperazinyl)butylamine 

Relevant articles and documents

Novel Potent Dopamine-Norepinephrine and Triple Reuptake Uptake Inhibitors Based on Asymmetric Pyran Template and Their Molecular Interactions with Monoamine Transporters

We have carried out a structural exploration of (2S,4R,5R)-2-(bis(4-fluorophenyl)methyl)-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol (D-473) to investigate the influence of various functional groups on its aromatic ring, the introduction of heteroc

The intramolecular addition of an aryl radical to a pyridine provides a short entry to toddaquinoline

The paper describes a synthetic approach to toddaquinoline, an unusual alkaloid from the root bark of Formosan Toddalia asiatica. Key steps are a cis-selective Wittig coupling and a trialkyltin mediated, intramolecular cyclisation of an aryl radical to C-

Substituted Pyran Derivatives

Certain 3,6-disubstituted and 2, 4, 5-trisubstituted pyran derivatives that exhibit potent activity on monoamine transport systems are provided. The 3, 6 and 2, 4, 5 pyrans are useful in probing the effects of their binding to monoamine transporter system

INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH

Provided herein are compounds having TNFα and/or PDE4 and/or B-RAF inhibitory activity, and compositions thereof. In particular, provided herein are compounds of the formula (I) and pharmaceutically acceptable salts, solvates, hydrates, clathrates, stereoisomers, polymorphs and prodrugs thereof, wherein Ar, R1, R2, R3, R4, n and Z are as described herein. Further provided herein are methods for treating or preventing various diseases and disorders by administering to a patient one or more TNFα and/or PDE4 and/or B-RAF inhibitors. In particular, provided herein are methods for preventing or treating cancer, inflammatory disorders, cognition and memory disorders and autoimmune disorders, or one or more symptoms thereof by administering to a patient one or more TNFα and/or PDE4 and/or B-RAF inhibitors.